PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPalpha SECRETION AND IMROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
The present disclosure relates to methods of administering compounds for treating conditions associated with amyloid processing such as Alzheimer's Disease. Methods are disclosed comprising the step of administering a macrocyclic lactone, a benzolactam, a pyrrolidinone or a combination thereof to a subject in need in an amount effective to decrease soluble Aβ-40 or Aβ-42, or to lower total amyloid precursor protein (“APP”). Methods are also disclosed further comprising the step of identifying a subject with increased soluble Aβ-40 or Aβ-42 levels, or elevated APP levels compared to a control population.
1 - 36 . (canceled)
37 . A method comprising the step of administering a macrocyclic lactone, a benzolactam, a pyrrolidinone or a combination thereof to a subject in need thereof in an amount effective to decrease soluble Aβ-40.
38 . The method of claim 37 , further comprising the step of identifying a subject with increased soluble Aβ-40 levels compared to a control population.
39 . The method of claim 37 , wherein the macrocyclic lactone, the benzolactam, the pyrrolidinone or the combination thereof decreases mean soluble Aβ-40 by about 35%.
40 . The method of claim 37 , wherein the macrocyclic lactone, the benzolactam, the pyrrolidinone or the combination thereof decreases the soluble Aβ-40 by between about 8% and 50%.
41 . The method of claim 38 , wherein the macrocyclic lactone, the benzolactam, the pyrrolidinone or the combination thereof decreases mean soluble Aβ-40 by about 35%.
42 . The method of claim 38 , wherein the macrocyclic lactone, the benzolactam, the pyrrolidinone or the combination thereof decreases the soluble Aβ-40 by between about 8% and 50%.
43 . The method of claim 37 , wherein the macrocyclic lactone is a bryostatin class or neristatin class compound.
44 . The method of claim 43 , wherein the bryostatin class compound is bryostatin-1 through bryostatin-18 or neristatin-1.
45 . The method of claim 38 , wherein the macrocyclic lactone is a bryostatin class or neristatin class compound.
46 . The method of claim 45 , wherein the bryostatin class compound is bryostatin-1 through bryostatin-18 or neristatin-1.
47 . The method of claim 37 , wherein the subject suffers from a neurological disease or disorder.
48 . The method of claim 47 , wherein the neurological disease is Alzheimer's Disease, multi-infarct dementia, the Lewy-body variant of Alzheimer's Disease with or without association with Parkinson's disease; Creutzfeld-Jakob disease, Korsakow's disorder, or attention deficit hyperactivity disorder.
49 . The method of claim 48 , wherein the neurological disease is Alzheimer's Disease.
50 . The method of claim 38 , wherein the subject suffers from a neurological disease or disorder.
51 . The method of claim 50 , wherein the neurological disease is Alzheimer's Disease, multi-infarct dementia, the Lewy-body variant of Alzheimer's Disease with or without association with Parkinson's disease; Creutzfeld-Jakob disease, Korsakow's disorder, or attention deficit hyperactivity disorder.
52 . The method of claim 51 , wherein the neurological disease is Alzheimer's Disease.
53 . A method comprising the step of administering a macrocyclic lactone, a benzolactam, a pyrrolidinone or a combination thereof to a subject in need thereof in an amount effective to decrease soluble Aβ-42.
54 . The method of claim 53 , further comprising the step of identifying a subject with increased soluble Aβ-42 levels compared to a control population.
55 . The method of claim 53 , wherein the macrocyclic lactone, the benzolactam, the pyrrolidinone or the combination thereof decreases mean soluble Aβ-42 by about 59%.
56 . The method of claim 53 , wherein the macrocyclic lactone, the benzolactam, the pyrrolidinone or the combination thereof decreases the soluble Aβ-42 by between about 25% and 77%.
57 . The method of claim 54 , wherein the macrocyclic lactone, the benzolactam, the pyrrolidinone or the combination thereof decreases mean soluble Aβ-42 by about 59%.
58 . The method of claim 54 , wherein the macrocyclic lactone, the benzolactam, the pyrrolidinone or the combination thereof decreases the soluble Aβ-42 by between about 25% and 77%.
59 . The method of claim 53 , wherein the macrocyclic lactone is a bryostatin class or neristatin class compound.
60 . The method of claim 59 , wherein the bryostatin class compound is bryostatin-1 through bryostatin-18 or neristatin-1.
61 . The method of claim 54 , wherein the macrocyclic lactone is a bryostatin class or neristatin class compound.
62 . The method of claim 61 , wherein the bryostatin class compound is bryostatin-1 through bryostatin-18 or neristatin-1.
63 . The method of claim 53 , wherein the subject suffers from a neurological disease or disorder.
64 . The method of claim 63 , wherein the neurological disease is Alzheimer's Disease, multi-infarct dementia, the Lewy-body variant of Alzheimer's Disease with or without association with Parkinson's disease; Creutzfeld-Jakob disease, Korsakow's disorder, or attention deficit hyperactivity disorder.
65 . The method of claim 64 , wherein the neurological disease is Alzheimer's Disease.
66 . The method of claim 54 , wherein the subject suffers from a neurological disease or disorder.
67 . The method of claim 66 , wherein the neurological disease is Alzheimer's Disease, multi-infarct dementia, the Lewy-body variant of Alzheimer's Disease with or without association with Parkinson's disease; Creutzfeld-Jakob disease, Korsakow's disorder, or attention deficit hyperactivity disorder.
68 . The method of claim 67 , wherein the neurological disease is Alzheimer's Disease.
69 . A method comprising the step of administering a macrocyclic lactone, a benzolactam, a pyrrolidinone or a combination thereof in an amount effective to lower total amyloid precursor protein (“APP”).
70 . The method of claim 69 , further comprising the step of identifying a subject with elevated APP levels compared to a control population.
71 . The method of claim 69 , wherein the macrocyclic lactone, the benzolactam, the pyrrolidinone or the combination thereof lowers mean total APP by about 40%.
72 . The method of claim 69 , wherein the macrocyclic lactone, the benzolactam, the pyrrolidinone or the combination thereof lowers the total APP by up to about 67%.
73 . The method of claim 70 , wherein the macrocyclic lactone, the benzolactam, the pyrrolidinone or the combination thereof lowers mean total APP by about 40%.
74 . The method of claim 70 , wherein the macrocyclic lactone, the benzolactam, the pyrrolidinone or the combination thereof lowers the total APP by up to about 67%.
75 . The method of claim 69 , wherein the macrocyclic lactone is a bryostatin class or neristatin class compound.
76 . The method of claim 75 , wherein the bryostatin class compound is bryostatin-1 through bryostatin-18 or neristatin-1.
77 . The method of claim 70 , wherein the macrocyclic lactone is a bryostatin class or neristatin class compound.
78 . The method of claim 77 , wherein the bryostatin class compound is bryostatin-1 through bryostatin-18 or neristatin-1.
79 . The method of claim 69 , wherein the subject suffers from a neurological disease or disorder.
80 . The method of claim 79 , wherein the neurological disease is Alzheimer's Disease, multi-infarct dementia, the Lewy-body variant of Alzheimer's Disease with or without association with Parkinson's disease; Creutzfeld-Jakob disease, Korsakow's disorder, or attention deficit hyperactivity disorder.
81 . The method of claim 80 , wherein the neurological disease is Alzheimer's Disease.
82 . The method of claim 70 , wherein the subject suffers from a neurological disease or disorder.
83 . The method of claim 82 , wherein the neurological disease is Alzheimer's Disease, multi-infarct dementia, the Lewy-body variant of Alzheimer's Disease with or without association with Parkinson's disease; Creutzfeld-Jakob disease, Korsakow's disorder, or attention deficit hyperactivity disorder.
84 . The method of claim 83 , wherein the neurological disease is Alzheimer's Disease.